Navigation Links
Roxane Laboratories, Inc. Announces the Launch of Anastrozole Tablets
Date:7/8/2010

COLUMBUS, Ohio, July 8 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1mg by the U.S. Food and Drug Administration.  The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Anastrozole Tablets are AB rated to ARIMIDEX® (anastrozole) tablets.  Annual sales of ARIMIDEX® are approximately $916.8 Million(1). ARIMIDEX® (anastrozole) is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer; First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer; treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Full prescribing information for Anastrozole Tablets is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people.  Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutica
'/>"/>

SOURCE Roxane Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
5. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
6. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
7. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
8. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
9. MO BIO Laboratories, Inc. Launches LifeGuard(TM) Soil Preservation Solution
10. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... DALLAS and NEW YORK ... PHARMACEUTICALS, INC. (OTCBB: ACCP), has signed an exclusive, ... for the development and commercialization of its proprietary ... new corporate management team and its intention to ... Biopharmaceuticals, Inc.™, and its plans to pursue a ...
(Date:9/22/2014)... DENVER , Sept. 22, 2014  Prostate cancer ... men, but it is easily treated when caught early ... not. That is why the Prostate Conditions Education ... men,s health and a leader in prostate cancer screening ... Cancer Awareness Week (PCAW) from September 22-27.  ...
Breaking Medicine Technology:Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3
... Patent Protects Very Low Dose Glucagon ahead of Phase 2 Clinical Trials ... ... SAN FRANCISCO, Jan. 8 DiObex, Inc., a privately held,biotechnology company developing ... from the U.S. Patent,and Trademark Office for the use of very low ...
... BOTHELL, Wash., Jan. 8 Nastech Pharmaceutical,Company Inc. ... enrollment for its,Phase 2 clinical trial of PYY3-36 ... obese patients at multiple clinical sites in the ... study. The,study is designed to evaluate three different ...
Cached Medicine Technology:DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia 2Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity 2Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity 3
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... living in Canada have a higher rate of heart ... while people, McMaster researchers have found. , The ... Association Journal (CMAJ Open) and may be found ... ethnic groups in the country is the more than ... about three percent of the population. They include people ...
(Date:9/22/2014)... -- Recent two-generation approaches to reducing poverty that ... attention from researchers, advocates, and foundations. By combining ... to move to jobs that offer a path ... education for children, these programs aim to improve ... to a new report from the National Center ...
(Date:9/22/2014)... 22, 2014 The R&D of cancer ... years. The statistically important data received from clinical research ... vaccines. The primary challenge to the development of such ... exact mechanism of how a human’s immune system works. ... in different individuals owing to known factors with genetics ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
Breaking Medicine News(10 mins):Health News:Looking ahead: Whole eye transplant under development 2Health News:Higher risk of heart disease for South Asians in Canada 2Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2
... Researchers and staff from Karolinska Institutet are contributing ... of everything from neuroscience to bioentrepreneurship. Carl Johan ... Institutet, is the founder and initiator of ESOF. ... decision-makers, researchers, journalists and the general public meet ...
... ... dedicated to ending malaria deaths and empowering communities, ONE bracelet at a time (Buy a ... Malaria, and encourages others to join in the fight against this deadly disease. Malaria is ... kills a child every 30 seconds. , ...
... suggests that shorter length of leukocyte telomeres chromosome markers ... of cancer and death from cancer, according to a study ... leukocyte is a type of blood cell. Telomeres are ... the replication and stability of the chromosome. Genetic factors and ...
... COLUMBUS, Ohio Scientists have designed a nanoparticle that appears ... effects. In lab experiments, the researchers have found that ... enough into a cell to allow genetic material to be ... is between 2 and 10 times more effective than ...
... linked rejection by a romantic partner to brain activity associated ... published in the July issue of the Journal of ... R. Korey Department of Neurology and of neuroscience at Albert ... author of the study. This is the third publication in ...
... ... of additional foot problems such as bunions, hammertoes, arthritis and calluses, and improve a ... Ankle Surgery. , ... Chicago, IL (Vocus) July 6, 2010 -- Treatment and prevention of adult flatfoot can ...
Cached Medicine News:Health News:News from Karolinska Institutet at ESOF 2010 2Health News:MALAIKA FOR LIFE Takes a Stand in Light of Cheryl Cole's Malaria Bout 2Health News:MALAIKA FOR LIFE Takes a Stand in Light of Cheryl Cole's Malaria Bout 3Health News:Length of biological marker associated with risk of cancer 2Health News:Scientists design new delivery device for gene therapy 2Health News:Scientists design new delivery device for gene therapy 3Health News:Scientists design new delivery device for gene therapy 4Health News:Study links romantic rejection with reward and addiction centers in the brain 2Health News:Don't Ignore Flat Feet,Study links this condition to painful foot maladies 2
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... The first step to treatment is ... is an innovative and quick, patient-friendly tool ... female urinary incontinence while minimizing patient discomfort. ... device features a new type of urethral ...
...
Medicine Products: